DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|rareLife solutions 606 Post Road East #397
Westport, CT 06880
|You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
The Veterans Health Administration exists to integrate health care services for those who served in the U.S. Armed Forces. Yet for many veterans, getting access to treatment for transthyretin amyloidosis, a rare disease caused by a buildup of abnormal proteins, is difficult.
As a health system, the VA covers a large proportion of transthyretin amyloidosis patients because the condition usually presents in older adults, particularly older men. It is not a secret that medications used in the treatment of transthyretin amyloidosis are very expensive, and the VA does an excellent job in requiring patients to be responsible for only small monthly co-pay.
The VA has the opportunity to lead the way in providing patient-centered care for the historically untreatable disease. It should, however, work for best patients’ care rather than restricting physicians and limiting patients’ access.
Veterans with transthyretin amyloidosis are fighters, having first served their country and then forced to battle a progressive and rare disease. They shouldn’t have to also fight for access to the health care they rightfully earned.
videos & visuals“TTR-FAP: The Link Between Neuropathy and Amyloidosis” – Webinarhttps://www.youtube.com/watch?v=AePB4Cjr...
videos & visualsPeripheral Neuropathy Symptoms, Diagnostic Tests, and Approved Treatments – ASG Webinar 7/11https://www.youtube.com/watch?v=K2TmwAfu...
news & meetingsFDA Approves Patisiran Infusion for Hereditary Transthyretin-Mediated AmyloidosisThe FDA announced that it has approved p...
educationCarpal Tunnel Syndrome and Associated Symptoms as First Manifestation of hATTR AmyloidosisBackground: Hereditary transthyretin am...
educationNormal Scores of Deep Breathing Tests: Beware of Dysrhythmia in Transthyretin AmyloidosisBackground: The heart rate (HR) respons...
educationHereditary Transthyretin AmyloidosisHereditary transthyretin (ATTR) amyloido...
educationPsychopathological Dimensions in Subjects With Hereditary ATTR V30M Amyloidosis and Their Relation With Life Events ...Background: Chronic physical illness ha...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.